

# Deepbridge Life Sciences SEIS

## Investment Objective

The Deepbridge Life Sciences SEIS aims to provide an opportunity to secure potentially attractive returns by investing in a diversified portfolio of early-stage life science companies, whilst taking advantage of the considerable income tax, capital gains tax, and inheritance tax benefits available under the Seed Enterprise Investment Scheme.

The Fund seeks to provide capital to companies with exciting new technologies that satisfy the needs of large and growing markets within the realms of biopharmaceuticals, biotechnology and medical technology.

Companies may be engaged within the following sectors:

- > Anti-viral drug discovery and development
- > Antibiotic drug discovery and development

- > Neurodegenerative disease therapeutics
- > Cancer diagnostics and therapeutics
- > Auto-immune and other metabolic disorders therapies

Key benefits of investment in the Fund include:

- > An engaged hands-on approach from an experienced commercialisation team
- > Free of manager fees to the Investor, up to 100% allocation of investor funds ensuring maximum tax efficiency for the investor
- > All SEIS tax advantages applicable, depending on personal circumstances
- > Target return of 250p for every 100p invested, a target IRR of >30% over a minimum 5 years.

Performance fee aligned to the investors' interests.

## Exit Strategy

The Deepbridge team believes that most exits in the technology sector will take place in the M&A space, and so aim to execute business models suitable for this exit route. To appear on potential acquirers' radars, Deepbridge seeks to invest in opportunities that have the potential of becoming either a threat or a complement to existing products on the market. Exits will be sought at the earliest opportunity after the third anniversary of the investment made, however, exit strategies will likely be implemented within 4-5 years from investment date.

## Fund Manager

Enterprise Investment Partners LLP

Enterprise Investment Partners LLP is a specialist smallcap investment boutique established over five years ago, whose activities include corporate finance, fund management and the design and promotion of tax-efficient investment products, with major emphasis on EIS. Enterprise has considerable experience of EIS and the tax-efficient industry, with particular expertise in the leisure, media, commercial property and renewable energy sectors. The three principals together have raised over £200m under EIS, VCT and other tax efficient structures over the last five years.

For more information please visit [www.enterprise-ip.com](http://www.enterprise-ip.com)

## Fund at a glance

### Scheme Categorisation

The Scheme is structured as a Discretionary Managed Service and the Information Memorandum can be found at [www.deepbridgecapital.com](http://www.deepbridgecapital.com)

### Target Return

250p per 100p invested, a gross equivalent target return of >30% per annum (not guaranteed) over a minimum 5 years.

### Scheme Strategy

Private Equity SEIS

### Investment Sector

Life Sciences

### Target Diversification

Ten investee companies targeted per investor to the portfolio.

### Nominee & Custody Arrangements

The Nominee: Woodside Nominees Limited  
The Custodian: Woodside

## Fees

No fees are levied against investors prior to investment, allowing up to 100% capital deployment and therefore full taxation benefits through the Enterprise Investment Scheme.

### Corporate Advisory and Arrangement Costs

Paid by the Investee Company: up to 2.5% of funds invested in that company

### Annual Maintenance Fee

Paid by the Investee Company: 2% p.a.

### Dealing and Custody Fees

Paid by the Investee Company: The Investment Adviser will charge each

Investee Company a dealing fee of 0.65% on the sale and purchase of shares, and a Custody Administration fee of 0.50% p.a. for the provision of custody services.

### Performance Incentive Fee

An incentive fee of 20% of the amount of cumulative cash returned, in excess of the amount of funds invested in the Investee Companies.

### Investor Marketing and Other Fees

The Manager reserves the right to levy additional fees to the Investee Company to meet any costs relating to investor marketing, additional

fundraising and administration, custody and services provided.

### Shares, Options & Warrants

The Manager may also seek to take shares, options or warrants in the Investee Companies either in lieu of any of the above charges or fees in addition and in line with standard industry practice.

All fees are stated excluding any VAT which may also be charged where applicable.

## Fund Provider

Deepbridge Advisers Limited

Deepbridge is a different kind of investment manager. We work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to assetbacked renewable energy projects. We also partner with innovative and committed management teams to help UK based companies realise their potential and become successful leading-edge businesses. Deepbridge operates across four principle divisions: disruptive technology, sustainable technologies, life sciences and renewable energy.

For further information please visit [deepbridgecapital.com](http://deepbridgecapital.com)

For further information please do not hesitate to

contact us on:

+44 (0) 20 7952 6685

[info@kuber.uk.com](mailto:info@kuber.uk.com)

[www.kuberventures.co.uk](http://www.kuberventures.co.uk)

### Important Notice

Please read the following information carefully as a professional adviser. The information contained in this document is for discussion purposes only for professional advisers and their clients, it is not for Retail Clients. EIS Portfolios are not suitable for all investors as the underlying investments are often illiquid and therefore high risk. Advice should always be sought from a professional adviser prior to investing. By proceeding through this document and accompanying Platform Guide you are agreeing to the terms and conditions. For purposes of compliance with the UK Financial Services and Markets ACT 2000 (FSMA), this material is communicated by Kuber Ventures; and the contents of this financial promotion have been approved for the purposes of section 21 of the FSMA by Sturgeon Ventures LLP which is authorised and regulated by the Financial Conduct Authority (FCA) and it has its trading office at Linstead House, 9 Disraeli Road, London SW15 2DR. Kuber Ventures Limited advisors are all regulated by the Financial Conduct Authority and can be found on [www.fca.gov.uk/fcaregister](http://www.fca.gov.uk/fcaregister) Kuber Ventures Limited FRN 574987 is an Appointed Representative of Sturgeon Ventures LLP which are Authorised and Regulated by the Financial Conduct Authority. Kuber Ventures Limited, 25 Sackville Street, London, W1S 3AX Registered number: 8693809, VAT: 175 9290 69.